We are committed to therapeutic progress to serve patient needs.
- Put patients and innovation at the heart of all our actions
- Foster our individual and collective commitment, the Group’s driving force
- Guarantee our independence and our capacity for long-term investment
- Be a Group with global reach
Through our actions, we contribute to transfer to future generations a world that can ensure access to quality health care for all.
Dare to innovate
We undertake to provide innovative therapeutic solutions. Driven by a pioneering spirit, we dare, we strive, and we accomplish together.
We prepare for the future by embracing human and environmental dimensions. Our concern for the health and fulfillment of all is our driving force.
Grow by sharing
Every opportunity to work together contributes to the common good. Whoever we are, wherever we are, we grow and develop by working together, building on one another’s experiences and contributions.
Commit to succeed
The continuous development of the Group is vital. Whatever challenges we face, we are committed to keeping our promises.
We are an international and independent pharmaceutical company governed by a non-profit foundation, with headquarters in Suresnes, France. Since opening our first laboratory in 1954, we have been committed to therapeutic progress to serve patient needs with the help of healthcare professionals. We strive to transmit to future generations a world that can ensure access to quality health care for all.
Operating in 150 countries, we have 22,000 employes worldwide and a revenue of 4.615 billion euros in 2019. Entirely independent, we invest each year an average of 25% of our total revenue (excluding generic activities) into Research and Development, and all profits are used for further development.
Corporate growth at Servier is driven by our continuous pursuit of innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes. We are a leading force in cardiology—number 2 in Europe, number 6 worldwide—and we aim to become a recognized player in oncology; we also manufacture high-quality generic medicines.
Our three research centers are continuously involved in creating, testing, and developing new medicinal products, which are manufactured and packaged in our 16 production centers around the world. 98% of Servier medicines active ingredients are synthesized in its own plant in Bolbec-Baclair in France. We have an active partnership policy in the field of biotechnology and we are investing in e-health through our internal WeHealth TM Digital Medicine initiative.
All our employees are driven by shared Values and guided by a common Vision. Together we share the passion of entrepreneurship and we are committed to therapeutic progress to serve patient needs.